Guardant Health, Inc. announced preliminary, unaudited results for the quarter and full year ended December 31, 2025.
The company reported fourth quarter revenue growth of 39%, driven by strong Oncology and Screening volume.
For the full year 2025, Guardant Health reported total revenue of approximately $981 million, marking an increase of 33%.
Total Revenue Growth
Total revenue increased by 33% in 2025 compared to the previous year.
Oncology Tests Increase
The company reported an increase of 34% in oncology tests conducted in 2025.
Shield Screening Tests
Guardant Health reported a significant growth in Shield screening tests, with approximately 87,000 tests conducted in 2025.
- Guardant Health experienced accelerated total revenue growth of 33% year-over-year in 2025.
- The company's momentum is expected to continue with the launch of innovative products in the Oncology business.
- Shield screening tests have shown strong momentum, providing valuable diagnostic solutions for colorectal cancer screening.
Guardant Health's significant revenue growth and strategic product launches position the company for continued success in the fight against cancer in 2026 and beyond.